News Search Results
Jan 10, 2025, 12:30 ET Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
efficacies comparable to the approved peptide GLP-1 drugs. About Regor Therapeutics Regor Therapeutics Group is a clinical-stage biotechnology company, headquartered in Cambridge, MA and with operations in Houston,
More news about: Regor Therapeutics
Jan 10, 2025, 11:03 ET University of Maryland, Baltimore and University of Maryland, College Park Announce $10 Million Joint Gift from Edward and Jennifer St. John and the Edward St. John Foundation for New Center for Translational Engineering and Medicine
transforming Baltimore's biotechnology landscape. By fostering groundbreaking research and cross-disciplinary collaboration, the center will not only advance medical science but also reinforce the critical role of the biotechnology sector in driving economic growth and scientific
More news about: University of Maryland
Jan 10, 2025, 10:45 ET Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and
More news about: Menarini Industrie Farmaceutiche Riunite
Jan 10, 2025, 10:39 ET Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and
More news about: Menarini Industrie Farmaceutiche Riunite
Jan 10, 2025, 09:00 ET Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
transformational oncology treatments to cancer patients, and Insilico Medicine ("Insilico"), a clinical stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the companies have entered into an exclusive licensing agreement granting Stemline the global rights to develop and
More news about: Insilico Medicine
Jan 10, 2025, 08:05 ET MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
Jan. 10, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that it is holding an Advisory Committee meeting today, at the 9th
More news about: MetaVia Inc.
Jan 10, 2025, 08:00 ET Diakonos Oncology to Present at Biotech Showcase 2025
HOUSTON, Jan. 10, 2025 /PRNewswire/ -- Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced
More news about: Diakonos Oncology Corp.
Jan 10, 2025, 08:00 ET Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)
Jan. 10, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Jan 10, 2025, 08:00 ET Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase
More news about: Intensity Therapeutics Inc.
Jan 10, 2025, 07:00 ET Marengo Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Mass., Jan. 10, 2025 /PRNewswire/ -- Marengo Therapeutics, Inc., a clinical-stage biotechnology company pioneering novel approaches for precision T cell activation, today announced that Zhen Su, M.D., MBA, the
More news about: Marengo Therapeutics
Jan 10, 2025, 07:00 ET Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
Mediar Therapeutics, Inc., a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli
More news about: Mediar Therapeutics
Jan 10, 2025, 07:00 ET Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
the skin, leading to an immune reaction and inflammation. About Nektar Therapeutics Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases.
More news about: Nektar Therapeutics
Jan 10, 2025, 06:00 ET Ouro Medicines Launches to Define the Future of Treatment for People with Immune-Mediated Diseases
SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Ouro Medicines, a biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, today announced its launch with $120
More news about: Ouro Medicines
Jan 10, 2025, 04:00 ET JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
Jan. 10, 2025 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the Center for Drug Evaluation (CDE)
More news about: JW Therapeutics
Jan 09, 2025, 20:30 ET Timberlyne Therapeutics Launches with a $180 Million Series A Financing to Advance CM313, a Potentially Best-in-Class Anti-CD38 Monoclonal Antibody, for Diseases of High Unmet Medical Needs
operations for our companies based on our long track record in biopharmaceutical leadership and operational roles spanning from small start-up biotechnology companies to multi-national pharmaceutical companies. Contacts For Timberlyne Therapeutics:
More news about: Timberlyne Therapeutics
Jan 09, 2025, 17:30 ET Veralox Therapeutics Expands Its Pipeline with the Exclusive Option to Acquire Nudge Therapeutics
Md., Jan. 9, 2025 /PRNewswire/ -- Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today that it has entered into an exclusive
More news about: Veralox Therapeutics
Jan 09, 2025, 16:01 ET FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025
2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation
Jan 09, 2025, 16:01 ET FDA's Center for Veterinary Medicine Grants Innocan Pharma a Fee Waiver for 2025
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation
Jan 09, 2025, 16:00 ET Orna Therapeutics Appoints Vikas Sinha to its Board of Directors
WATERTOWN, Mass., Jan. 9, 2025 /PRNewswire/ -- Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of circular RNA medicines and unprecedented lipid nanoparticle (LNP) delivery solutions
More news about: Orna Therapeutics
Jan 09, 2025, 13:57 ET BARDA and Partner Therapeutics continue partnership around development of LEUKINE® (sargramostim, rhu GM-CSF) to potentially improve patient care for sepsis
metabolic laboratory abnormalities, edemaABOUT PARTNER THERAPEUTICSPartner Therapeutics, Inc. (PTx), an integrated biotechnology company, focuses on development and commercialization of late-stage therapeutics to improve health outcomes in treatment of cancer and other serious
More news about: Partner Therapeutics, Inc.
Jan 09, 2025, 12:13 ET healthŌme, Inc. Announces Rename and Rebrand as Kadance, Inc.
HudsonAlpha Institute for Biotechnology in Huntsville, Alabama.
More news about: Kadance, Inc.
Jan 09, 2025, 10:55 ET etherna Announces Strategic Multi-Target Collaboration with Dropshot Therapeutics
transformative therapies to improve patients' lives. About Dropshot TherapeuticsDropshot Therapeutics is an early stage biotechnology company dedicated to developing innovative RNA-based therapeutics for heart and kidney diseases. The company is based near Boston,
More news about: etherna
Jan 09, 2025, 10:45 ET Esphera SynBio Announces New Project to Advance Next Generation mRNA Vaccine Development, supported by the CQDM Quantum Leap program
www.cqdm.org and join us on Twitter/X @CQDM_Canada and LinkedIn. About Esphera SynBio Inc. Esphera is a seed stage Canadian biotechnology combining innovative technologies developed at McMaster University and the Ottawa Hospital Research Institute. These
More news about: Esphera SynBio Inc
Jan 09, 2025, 10:30 ET Global Biotechnology Market Outlook 2025: Driving Growth at 13.0% CAGR | MarketsandMarkets™
proteins.Sustainability is one of the major driving factors in the biotechnology industry, shaping the management raw materials, packaging, and bioprocessing. Due to increasing environmental concern and regulations, biotechnology manufacturers will be pushed to adopt more sustainable practices across
More news about: MarketsandMarkets
Jan 09, 2025, 09:00 ET Coronado Research announce appointment of Jo Marshall as EVP Data Services and Advanced Analytics
Coronado Research Coronado Research is a consultancy-led, professional services organisation, which provides support to pharmaceutical, biotechnology, and medical device companies. Our objective is to optimise the clinical development process by leveraging all the data available using AI, ML,
More news about: Coronado Research